Your session is about to expire
← Back to Search
Other
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC Trial)
N/A
Recruiting
Led By Lauren Balmert Bonner, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Summary
This trial aims to confirm if hyperbaric oxygen therapy can improve remission and reduce surgery for ulcerative colitis patients in hospital. It also looks at how it impacts immune and microbial functions.
Who is the study for?
This trial is for adults aged 18-85 with known or newly diagnosed Ulcerative Colitis (UC) who are hospitalized due to a severe flare-up. They must be able to start hyperbaric oxygen therapy within 48 hours after beginning steroid treatment and cannot have certain colitis types, complications needing urgent surgery, major organ impairments, recent investigational drug use, pregnancy/nursing status, or active COVID-19.
What is being tested?
The study tests if Hyperbaric Oxygen Therapy (HBOT), which involves breathing pure oxygen under pressure to increase tissue oxygen levels, can help hospitalized UC patients avoid worsening conditions and the need for more intense treatments. It compares HBOT's effectiveness against a sham air treatment in improving remission rates.
What are the potential side effects?
While not specified here, common side effects of HBOT may include ear pain or damage due to increased pressure, temporary vision changes, fatigue and claustrophobia from being inside the chamber. Rarely it can cause lung collapse or seizures from too much oxygen.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinical response defined as complete resolution of rectal bleeding and improvement in stool frequency, without need for in-hospital biologics, small molecules, or colectomy by study day 5
Secondary study objectives
Change in inflammation, as measured by C-reactive protein
Change in inflammation, as measured by fecal calprotectin
Clinical Remission
+20 moreSide effects data
From 2018 Phase 2 trial • 20 Patients • NCT0236395910%
Repeat bronchoscopy due to bleeding during biopsy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Hyperbaric Oxygen, Airway Biopsy
No Hyperbaric Oxygen, Airway Biopsy
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Hyperbaric Oxygen TherapyExperimental Treatment1 Intervention
Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute "air breaks" (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days.
Group II: Sham Hyperbaric AirPlacebo Group1 Intervention
This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute "air breaks" to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hyperbaric Oxygen Therapy
2016
Completed Phase 4
~800
Find a Location
Who is running the clinical trial?
Northwestern UniversityLead Sponsor
1,640 Previous Clinical Trials
957,446 Total Patients Enrolled
2 Trials studying Colitis
125 Patients Enrolled for Colitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,439 Previous Clinical Trials
4,324,698 Total Patients Enrolled
16 Trials studying Colitis
5,245 Patients Enrolled for Colitis
Lauren Balmert Bonner, PhDPrincipal InvestigatorNorthwestern University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I need surgery urgently due to a complication.I have been diagnosed with toxic megacolon.I have been diagnosed with a specific type of colitis.I have tried and not responded to 3 or more types of advanced cancer treatments.I cannot receive steroids through an IV.I have a serious heart, kidney, nerve, hormone, lung, or liver condition that could make HBOT risky for me.I am between 18 and 85 years old.I am currently infected with COVID-19.I am not willing to complete a course of hyperbaric oxygen therapy.I am hospitalized for a severe flare-up of ulcerative colitis.I am not pregnant or nursing.I agree to start HBOT within 48 hours after beginning IV steroids.
Research Study Groups:
This trial has the following groups:- Group 1: Hyperbaric Oxygen Therapy
- Group 2: Sham Hyperbaric Air
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger